Catalyst

Slingshot members are tracking this event:

Alexion Pharmaceuticals (ALXN) Eculizumab Phase 3 data for relapsing NMOSD in PREVENT trial due mid 2018

Source Link:
http://news.alexionpharma.com/press-release/financial-news/alexion-reports-fourth-quarter-and-full-year-2017-results-and-provides-

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ALXN Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 24, 2018
Occurred Source:
https://www.businesswire.com/news/home/20180924005283/en/Alexion-Announces-Successful-Phase-3-PREVENT-Study
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Prevent Trial, Eculizumab, Phase 3 Study, Nmosd
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.